Generex Data Presented At American Association for Cancer Research 100th Annual Meeting

WORCESTER, Mass., April 20, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology
Corporation (Nasdaq:GNBT) (www.generex.com) announced today that Antigen
Express, Inc., its wholly-owned immunotherapeutics subsidiary, has presented
recent pre-clinical findings on a novel immunotherapeutic vaccine for human
papilloma virus (HPV)-induced cancers. The study, entitled: "Ii-Key/HPV16 E7
hybrid peptide vaccine for HPV16+ cancers," was presented by Dr. Minzhen Xu,
Ph.D., the Antigen Express Vice-President of Biology, at the 100th Annual
Meeting of the American Association for Cancer Research (www.aacr.org) in
Denver, CO, being held from April 18-22, 2009.

The AACR 100th Annual Meeting 2009, with the theme of "Science, Synergy, and
Success," highlights the best cancer science and medicine from institutions all
over the world.

The Antigen Express study reports on the identification of a modified peptide
vaccine with the potential to treat patients with HPV induced cancers. In
particular, a fragment of the HPV16 E7 protein, which is involved in the
tumorigenic activity of the virus, was modified by proprietary Antigen Express
technology to enhance stimulation of CD4+ T helper cells. The modified vaccine
peptide was roughly 5-fold more potent than the unmodified peptide in the
generation of antigen-specific T helper cells in a pre-clinical mouse model.
Furthermore, the increase in antigen specific T helper cells were associated
with significantly increased killing of HPV antigen-presenting target cells.

Antigen-specific stimulation of T helper cells is critical in the generation of
an effective anti-tumor response. While vaccines have been developed that are
effective at preventing infection by HPV, no current vaccine is of benefit in
patients with cervical or other cancers induced by HPV. In addition, the
availability of a synthetic peptide vaccine may be helpful in promoting the more
widespread use of a prophylactic HPV vaccine, which has been hindered by the
cost of the existing vaccine.

Antigen Express is currently conducting a randomized Phase II trial of a
similarly modified fragment of the HER2 protein (AE37) in breast cancer
patients, a Phase I trial in prostate cancer patients, and another Phase I trial
in breast or ovarian cancer patients wherein AE37 is combined with another
peptide vaccine. In the studies performed to date, the immunotherapeutic vaccine
has been found to be safe, well tolerated, and produces the desired
immunological response. A Phase I trial of a synthetic peptide vaccine for H5N1
avian influenza is also underway.

About Generex Biotechnology Corporation

Generex is engaged in the research, development and commercialization of drug
delivery systems and technologies. Generex has developed a proprietary platform
technology for the delivery of drugs into the human body through the oral cavity
(with no deposit in the lungs). The Company's proprietary liquid formulations
allow drugs typically administered by injection to be absorbed into the body by
the lining of the inner mouth using the Company's proprietary RapidMist(tm)
device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)),
which is available for sale in India and Ecuador for the treatment of subjects
with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several
sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of
Generex. The core platform technologies of Antigen Express comprise
immunotherapeutics for the treatment of malignant, infectious, allergic, and
autoimmune diseases. For more information, visit the Generex website at
www.generex.com or the Antigen Express website at www.antigenexpress.com.

The Generex Biotechnology Corp. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3831

Safe Harbor Statement

This release and oral statements made from time to time by Generex
representatives in respect of the same subject matter may contain
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements can be identified by
introductory words such as "expects," "plans," "intends," "believes," "will,"
"estimates," "forecasts," "projects," or words of similar meaning, and by the
fact that they do not relate strictly to historical or current facts.
Forward-looking statements frequently are used in discussing potential product
applications, potential collaborations, product development activities, clinical
studies, regulatory submissions and approvals, and similar operating matters.
Many factors may cause actual results to differ from forward-looking statements,
including inaccurate assumptions and a broad variety of risks and uncertainties,
some of which are known and others of which are not. Known risks and
uncertainties include those identified from time to time in the reports filed by
Generex with the Securities and Exchange Commission, which should be considered
together with any forward-looking statement. No forward-looking statement is a
guarantee of future results or events, and one should avoid placing undue
reliance on such statements. Generex undertakes no obligation to update publicly
any forward-looking statements, whether as a result of new information, future
events or otherwise. Generex cannot be sure when or if it will be permitted by
regulatory agencies to undertake additional clinical trials or to commence any
particular phase of clinical trials. Because of this, statements regarding the
expected timing of clinical trials cannot be regarded as actual predictions of
when Generex will obtain regulatory approval for any "phase" of clinical trials.
Generex claims the protection of the safe harbor for forward-looking statements
that is contained in the Private Securities Litigation Reform Act.

-0-
CONTACT: Generex Biotechnology Corporation
Investor Relations Contact:
American Capital Ventures, Inc.
Howard Gostfrand
1-877-918-0774

Avalanche Strategic Communications
Media Contact:
Angelene Taccini
201-488-0049